HC Wainwright Reaffirms “Buy” Rating for Delcath Systems (NASDAQ:DCTH)

HC Wainwright reaffirmed their buy rating on shares of Delcath Systems (NASDAQ:DCTH) in a report published on Monday morning,Benzinga reports. They currently have a $22.00 target price on the stock. HC Wainwright also issued estimates for Delcath Systems’ FY2028 earnings at $1.46 EPS.

A number of other equities analysts have also weighed in on DCTH. Stephens restated a “buy” rating on shares of Delcath Systems in a research report on Friday, October 18th. Canaccord Genuity Group restated a “buy” rating and set a $21.00 target price on shares of Delcath Systems in a report on Friday, October 18th. Finally, StockNews.com raised Delcath Systems from a “sell” rating to a “hold” rating in a report on Friday, October 25th. One investment analyst has rated the stock with a hold rating and four have assigned a buy rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $21.50.

Delcath Systems Stock Performance

Shares of DCTH stock opened at $9.41 on Monday. Delcath Systems has a fifty-two week low of $2.25 and a fifty-two week high of $12.88. The stock’s fifty day moving average is $9.74 and its two-hundred day moving average is $8.43.

Institutional Trading of Delcath Systems

A number of hedge funds and other institutional investors have recently made changes to their positions in the company. Riverwater Partners LLC purchased a new position in Delcath Systems in the third quarter worth approximately $161,000. Levin Capital Strategies L.P. grew its holdings in shares of Delcath Systems by 12.2% during the 1st quarter. Levin Capital Strategies L.P. now owns 54,969 shares of the company’s stock worth $262,000 after purchasing an additional 5,969 shares during the period. Cubist Systematic Strategies LLC purchased a new position in shares of Delcath Systems during the 2nd quarter worth $370,000. Renaissance Technologies LLC acquired a new stake in shares of Delcath Systems during the 2nd quarter worth about $694,000. Finally, Marshall Wace LLP raised its holdings in Delcath Systems by 7.0% in the 2nd quarter. Marshall Wace LLP now owns 92,731 shares of the company’s stock valued at $776,000 after buying an additional 6,066 shares during the period. Institutional investors and hedge funds own 61.12% of the company’s stock.

Delcath Systems Company Profile

Delcath Systems, Inc, an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company’s lead product candidate is HEPZATO KIT, a melphalan for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects.